Onpattro Now Will Be Reimbursed for Most Patients in Canada

Onpattro Now Will Be Reimbursed for Most Patients in Canada

308717

Onpattro Now Will Be Reimbursed for Most Patients in Canada

Onpattro (patisiran) is now reimbursed for patients with familial amyloid polyneuropathy (FAP) living across most regions of Canada, according to Alnylam Pharmaceuticals, the therapy’s developer. The announcement comes following a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux (INESSS), two agencies that help guide healthcare policy decisions in Canada. “We are pleased to report that the vast majority…

You must be logged in to read/download the full post.